Journal of Antimicrobial Chemotherapy 2003-03-01

Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.

Gioia S Babini, Meifang Yuan, Lucinda M C Hall, David M Livermore

Index: J. Antimicrob. Chemother. 51 , 605-612, (2003)

Full Text: HTML

Abstract

MICs of piperacillin/tazobactam are conventionally determined by varying the concentration of piperacillin in the presence of a fixed 4 mg/L tazobactam. When tested in this way, the MIC distribution for Klebsiella isolates with extended-spectrum beta-lactamases (ESBLs) is strongly bimodal, such that many producers are inhibited at 16 + 4 mg/L whilst others require MICs of > or =512 + 4 mg/L. When, however, piperacillin/tazobactam was tested as a fixed 8:1 ratio, the MIC distribution became unimodal. If clavulanate 4 mg/L was combined with piperacillin, a unimodal MIC distribution was seen for ESBL-producing Klebsiella spp. but a bimodal distribution arose if the clavulanate concentration was reduced to 0.25 mg/L. These data for alternative combinations suggested that the bimodal MIC distribution seen for piperacillin + tazobactam 4 mg/L was a titration effect, not a reflection of some ESBLs being resistant to tazobactam. Even within single strains, as defined by serotype and DNA fingerprints, there was considerable variation in susceptibility to piperacillin + tazobactam 4 mg/L, with some representatives highly susceptible and others highly resistant. Some of the more resistant representatives produced more of their ESBL, or had a greater number of beta-lactamase types, but these associations were not universal. Elevated resistance to piperacillin + tazobactam was not associated with porin change in any ESBL producer examined, but has been found by others.


Related Compounds

  • Tazobactam Sodium...

Related Articles:

Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.

2015-04-01

[Clin. Chem. Lab Med. 53(5) , 781-91, (2015)]

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.

2011-01-01

[Nucleic Acids Res. 39 , D1035-41., (2011)]

Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.

2001-06-11

[Biochim. Biophys. Acta 1547 , 196, (2001)]

In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum β-lactams. . Roland, R. K., et al.

[J. Infect. Dis. 4 , 226, (2000)]

More Articles...